Data from Pharmawand - Curated by EPG Health - Date added 14 March 2018

Novartis announces two subanalyses from the CANTOS trial which suggest that canakinumab may be a therapy for the highest cardiovascular risk patients. In the two analyses—one in patients with chronic kidney disease and the other in diabetes—canakinumab "substantially" reduced the risk of major adverse cardiovascular events, Brigham and Women's Hospital researchers said at the American College of Cardiology conference in Orlando. Both groups of patients are at higher risk of heart attack, stroke and other cardiovascular complications.

In chronic kidney disease patients, canakinumab reduced the risk of events by 18% over placebo. For patients with diabetes, canakinumab cut risks by 10% in a composite measure of CV events, known as MACE, while those with prediabetes experienced a 14% risk reduction.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Type 2 Diabetes

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.



Learn about the complex factors influencing development of obesity.

+ 4 more

Load more

Related Content